Regional One Health’s Center for Innovation is giving women between ages 18 to 60 an opportunity to participate in a validation clinical study to advance the treatment of vaginal yeast infections, a condition that impacts 75 percent of women at least once in their lifetime.
The Center for Innovation has partnered with Coologics, a company that is developing a new product that aims to treat vaginal yeast infection in 5-7 days and provide relief that lasts 30-40 days post-treatment.
The clinical study is open to healthy women ages 18-60 who are suffering from symptoms consistent with the diagnosis of vulvovaginal candidiasis (VVC), bacterial vaginosis (BV) or VVC/BV combined. These include itching and discomfort, burning, redness, swelling, pain or burning during urination or sex, and a thick white discharge.
Participants must be able to attend three separate in-clinic visits over a period of about 45 days. The study will be held at Regional One Health’s downtown Memphis campus.
The study is designed to give Coologics an opportunity to test its treatment with patients in a real-world health care environment, which is a key tenet of the Center for Innovation’s mission.
Through the center’s Access Incubator program, external innovators like Coologics gain access to resources within the Regional One Health system so they can generate, develop and test ideas to determine if they benefit patients and the health care industry.
Participants in the study will contribute valuable information that may advance the treatment of vaginal yeast infection, helping themselves and others who struggle with this common condition.